Oppenheimer & Co. Inc. lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.3% during the first quarter, Holdings Channel reports. The firm owned 1,016,979 shares of the biopharmaceutical company’s stock after selling 45,697 shares during the period. Gilead Sciences comprises about 2.0% of Oppenheimer & Co. Inc.’s investment portfolio, making the stock its 2nd largest position. Oppenheimer & Co. Inc.’s holdings in Gilead Sciences were worth $69,073,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. North Tide Capital LLC raised its stake in shares of Gilead Sciences by 100.0% in the first quarter. North Tide Capital LLC now owns 1,000,000 shares of the biopharmaceutical company’s stock worth $67,920,000 after buying an additional 500,000 shares during the period. Edmond DE Rothschild Holding S.A. increased its position in shares of Gilead Sciences by 18.4% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 1,485,504 shares of the biopharmaceutical company’s stock worth $100,895,000 after buying an additional 230,714 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Gilead Sciences by 3.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 4,404,045 shares of the biopharmaceutical company’s stock worth $299,123,000 after buying an additional 150,318 shares in the last quarter. Summit Street Capital Management LLC increased its position in shares of Gilead Sciences by 17.7% in the first quarter. Summit Street Capital Management LLC now owns 48,492 shares of the biopharmaceutical company’s stock worth $3,294,000 after buying an additional 7,283 shares in the last quarter. Finally, Stockman Wealth Management Inc. increased its position in shares of Gilead Sciences by 21.4% in the first quarter. Stockman Wealth Management Inc. now owns 52,030 shares of the biopharmaceutical company’s stock worth $3,534,000 after buying an additional 9,173 shares in the last quarter. 74.06% of the stock is currently owned by institutional investors.

Gilead Sciences, Inc. (GILD) traded down 1.04% during midday trading on Thursday, hitting $73.13. The stock had a trading volume of 2,019,612 shares. The company’s 50 day moving average is $72.16 and its 200 day moving average is $68.73. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $82.10. The company has a market cap of $95.50 billion, a price-to-earnings ratio of 7.94 and a beta of 1.21.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. During the same period in the previous year, the business earned $3.08 earnings per share. The company’s revenue was down 8.2% on a year-over-year basis. On average, equities analysts anticipate that Gilead Sciences, Inc. will post $8.76 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be given a dividend of $0.52 per share. The ex-dividend date is Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.81%. Gilead Sciences’s dividend payout ratio is currently 22.58%.

WARNING: “Oppenheimer & Co. Inc. Reduces Stake in Gilead Sciences, Inc. (GILD)” was posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.watchlistnews.com/oppenheimer-co-inc-reduces-stake-in-gilead-sciences-inc-gild/1470756.html.

A number of brokerages have recently weighed in on GILD. BidaskClub downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $84.00 price target on the stock in a report on Friday, July 28th. Cowen and Company reiterated an “outperform” rating and set a $90.00 price target on shares of Gilead Sciences in a report on Thursday, July 27th. Deutsche Bank AG reiterated a “buy” rating and set a $81.00 price target (up previously from $79.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $82.00 price target (up previously from $72.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Twelve investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Gilead Sciences presently has a consensus rating of “Buy” and an average target price of $80.31.

In other Gilead Sciences news, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the completion of the transaction, the executive vice president now directly owns 102,988 shares in the company, valued at $7,318,327.28. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the transaction, the insider now owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 206,666 shares of company stock valued at $15,223,184. Company insiders own 1.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.